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Abstract
Myelodysplastic syndrome (MDS) is characterized by ineffective hematopoiesis and hyperplastic bone marrow. Complete loss
or interstitial deletions of the long arm of chromosome 5 occur frequently in MDS. One candidate tumor suppressor on 5q is
the mammalian Diaphanous (mDia)-related formin mDia1, encoded by DIAPH1 (5q31.3). mDia-family formins act as effectors
for Rho-family small GTP-binding proteins including RhoB, which has also been shown to possess tumor suppressor activity.
Mice lacking the Drf1 gene that encodes mDia1 develop age-dependent myelodysplastic features. We crossed mDia1 and
RhoB knockout miceto test whether the additional loss of RhoB expression wouldcompound the myelodysplastic phenotype.
Drf1
2/2RhoB
2/2 mice are fertile and develop normally. Relative to age-matched Drf1
2/2RhoB
+/2 mice, the age of
myelodysplasia onset was earlier in Drf1
2/2RhoB
2/2 animals—including abnormally shaped erythrocytes, splenomegaly, and
extramedullary hematopoiesis. In addition, we observed a statistically significant increase in the number of activated
monocytes/macrophages in both the spleen and bone marrow of Drf1
2/2RhoB
2/2 mice relative to Drf1
2/2RhoB
+/2 mice.
These data suggest a role for RhoB-regulated mDia1 in the regulation of hematopoietic progenitor cells.
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Introduction
mDia-family formins assemble linear actin filaments and
modulate microtubule dynamics in response to adhesive and
proliferative stimuli [1]. They are regulated by Rho-family small
GTP-binding proteins such as RhoB [2,3]. Rho GTPases activate
formins through direct binding and disruption of an autoinhibitory
mechanism mediated by regulatory domains that flank the actin/
microtubule-binding formin homology-2 (FH2) domain [1]. While
the roles of mDia formins in directed cell migration, cell division,
and development are well established [4], only recently have gene-
targeting experiments in mice revealed roles for mDia family
formins in immune and myeloid cell proliferation [5,6,7].
The DIAPH1 gene encoding human mDia1 (located at 5q31.3)
lies between the two commonly deleted regions mapped by
conventional cytogenetics in myelodysplastic syndrome (MDS)
patient samples [8]. 5q- MDS is characterized by peripheral
cytopenias and ineffective hematopoiesis [9]. How defects in one
or more 5q genes trigger MDS or contribute to malignant
progression in conjunction with additional chromosomal abnor-
malities remains unknown [10]. Gene targeting experiments on
the murine DIAPH1 homolog Drf1 show that loss of mDia1
expression impairs the growth control of hematopoietic progen-
itors [6]. However, the specific mechanism by which loss of mDia1
expression triggers the MDS-like phenotype is currently under
investigation.
The small GTPase RhoB binds to both mDia1 and mDia2 on
endosomes and has a role in endosome trafficking [2,3]. RhoB also
plays an important role in the apoptotic response to DNA damage
[11], and loss of RhoB expression has been shown to correlate with
late-stage malignancy [12,13]. Mice lacking RhoB alone do not show
any signs of myelodysplasia or any developmental or fertility defects,
but Ras-transformed mouse embryonic fibroblasts (MEFs) from these
mice are resistant to apoptosis in the presence of farnesyltransferase
inhibitors (FTIs), doxorubicin, or taxol [14,15,16]. Together, these
studies suggest RhoB possesses tumor suppressor activity.
In this study, we hypothesized that the myelodysplasia observed in
Drf1-null mice would be enhanced by the additional loss of one of its
regulators, RhoB. After examination of the peripheral blood, bone
marrow, and spleen hematopoietic progenitor cells, we show that
Drf1
2/2RhoB
2/2micedevelopage-dependentmyelodysplasiabefore
Drf1
2/2RhoB
+/2 mice. These results are consistent with a model for
disease progression in MDS that includes the alteration of multiple
tumor suppressors in hematopoietic stem or progenitor cells.
Materials and Methods
Gene targeting
The gene targeting and genotyping of Drf1-null mice were
exactly as previously described [17]; targeting and genotyping of
RhoB-null mice were as described in [15]. The mice used in this
study were a mixed 129/B6 genetic background. For all
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2/2RhoB
+/2 and six
Drf1
2/2RhoB
2/2 mice at 100 days of age, and from eight Drf1
2/2
RhoB
+/2 and nine Drf1
2/2RhoB
2/2 mice at 400 days of age.
Ethics Statement
All experiments performed were approved in advance by the
Van Andel Research Institute Institutional Animal Care and Use
Committee.
Flow cytometry analysis
Peripheral blood, bone marrow, and splenic single-cell suspen-
sions were characterized by flow cytometric analysis. Peripheral
blood was extracted from the heart using a syringe equipped with
a fine gauge needle. Bone marrow was flushed from femurs using a
syringe with a fine gauge needle and 3 mL of PBS. Single-cell
suspensions of the spleen were obtained by mincing tissue with
glass slides and subsequent passage and scraping of tissue in a
ThermoShandon biopsy bag (Thermo Fisher Scientific).
Cells were incubated for 15 min at 20uC in the dark. Incubation
was followed by addition of 16 FACSLyse reagent (Becton
Dickinson) for 15 min at 20uC in the dark. After RBC lysis, the
remaining cells were washed in 2 mL PBS with 0.1% sodium
azide. Cells were fixed in 1.0% methanol-free formaldehyde
(Polysciences, Inc.) in PBS containing 0.1% bovine serum albumin
and refrigerated at 4.0uC until acquisition. Appropriate subclass
and negative controls were used to detect nonspecific binding of
antibody and autofluorescence. A minimum of 10,000 events for
fresh mononuclear cells and 5,000 events for splenic cells were
acquired. Flow cytometric analyses were conducted using either a
FACSCalibur 4-color or a FACSAria 12-color flow cytometer
(Becton Dickinson). Data were analyzed using Becton Dickinson
CellQuest Pro and FACSDiVa software.
Monoclonal antibodies
The following monoclonal antibodies were used: anti-
CD29APC from BioLegend; anti-CD45PerCP (30-F11), anti-
CD41FITC (MWReg30), anti-CD71FITC (C2), anti-CD74FITC
(In-1), anti-TER-119PE (Ly-76, Ter-119), anti-CD13PE (R3-242),
anti-CD19PE (1D3), and anti-CD11bAPC (D12) from BD
PharMingen; and anti-F4/80 (BM8), anti-CD8aPE (5H10), anti-
CD4APC (RM4-5), anti-CD34APC (MEC14.7), and anti-
CD3FITC (500A2) from Invitrogen/Caltag Laboratories.
Cell cycle analysis, complete blood count (CBC), and
statistics
Cell cycle analyses used propidium iodide (Sigma) in a modified
Vindelov’s preparation. A minimum of 10,000 events were
collected by flow cytometry. Data were analyzed using Becton
Dickinson CellQUEST Pro and Verity House ModFIT LT
software. CBC analysis was performed using a VetScan HM2
Hematology System (Abaxis). All statistical analysis was performed
using the one-tailed Mann Whitney test for significance. Each
point on scatter plots represent a single mouse, and each plot
includes a horizontal line to indicate the median of the data.
Scatter plots and statistics were performed using GraphPad Prism
5.0 software.
Results
We previously reported that Drf1
2/2 and Drf1
+/2 mice develop
age-dependent myelodysplasia, typically around 450 days of age
[6]. We asked whether the additional homozygous loss of RhoB
would enhance disease progression relative to Drf1-null mice that
still contain a functional allele of RhoB. Previous reports have
shown that RhoB
+/2 cells are indistinguishable from RhoB
+/+ cells
in their apoptotic response to DNA damage [16]. We character-
ized multiple mice of each genotype at 100 and 400 days of age to
assess the presence of myelodysplastic features.
Upon necropsy, we found that several 400-day-old Drf1
2/2
RhoB
2/2 mice had splenomegaly, as determined by whole spleen
weight compared to that of Drf1
2/2RhoB
+/2 mice (Fig. 1A).
Pathological examination of H&E-stained splenic sections showed
significant dysplasia, and there was often atrophy of the white pulp
with poorly formed germinal centers (Fig. 1B). Splenic sections
from Drf1
2/2RhoB
2/2 mice also revealed abnormal ratios of
myeloid and erythroid composition (frequently a myeloid:ery-
throid ratio greater than 2.0) and an increased presence of
extramedullary hematopoiesis (EMH) (Fig. 1C).
Based on our previous work in Drf1-null mice [6] and the recent
finding that the mDia2 formin contributes to erythroblast
enucleation [18], we examined the peripheral blood to determine
if there was morphological evidence of erythrocyte dysplasia.
Peripheral blood smears from Drf1
2/2RhoB
2/2 mice showed a
marked elevation in abnormally shaped erythrocytes compared
with blood from Drf1
2/2RhoB
+/2 mice. The erythrocytes were
often spiked (echinocyte) or teardrop in appearance (Fig. 2A),
consistent with dysplastic features observed in patients with MDS.
Drf1
2/2RhoB
+/2 mice did show signs of dysplasia at 400 days,
with several teardrop-shaped erythrocytes, but to a lesser extent
than Drf1
2/2RhoB
2/2 mice. CBC analysis of peripheral blood
Figure 1. Mice lacking Drf1 and RhoB develop splenomegaly
and splenic disorganization. Drf1
2/2RhoB
2/2 and Drf1
2/2RhoB
+/2
mice were necropsied at 100 and 400 days of age. A. Spleens were
removed from mice and weighed immediately. Each point on scatter
plot represents data from a single mouse. B. Formalin-fixed spleens
from 400-day-old mice were paraffin-embedded and stained with H&E.
Sections shown are at 106magnification. C. Splenic sections from B, but
at 406magnification.
doi:10.1371/journal.pone.0007102.g001
RhoB/mDia1 Knockout Mice
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2/2
RhoB
2/2 mice relative to that of Drf1
2/2RhoB
+/2 mice at 400
days of age (Fig. 2B). Abnormal platelet counts are sometimes
observed in certain subsets of MDS, but we did not observe any
significant differences in these mice (Fig. 2C).
We then focused our analysis specifically on the bone marrow
and spleen to examine myelopoiesis in these compartments. Flow
cytometry was used to determine the percentage of lymphocytes,
monocytes, and granulocytes based on the pan-leukocyte marker
CD45. Using the gating strategy outlined previously [6], we found
that 400-day-old Drf1
2/2RhoB
2/2 mice had an increased
percentage of granulocytes and a concomitant decrease in
lymphocytes in the bone marrow compartment (Fig. 3A). Analysis
of splenic single-cell suspensions isolated from 400-day-old mice
showed a similar increase of granulocytes in Drf1
2/2RhoB
2/2
mice (Fig. 3B).
To further examine potential differences in myelopoiesis
between Drf1
2/2RhoB
+/2 mice and Drf1
2/2RhoB
2/2 mice, we
performed flow cytometry on cells from the bone marrow and
spleen to detect levels of F4/80 (a pan macrophage marker) and
CD11b (integrin aM; monocyte development marker). By 400
days of age, Drf1
2/2RhoB
2/2 mice had an increased percentage of
F4/80
+ cells in the spleen, but we observed no significant
difference in the bone marrow (Fig. 3C). On the other hand,
CD11b
+ cells were significantly elevated in both the marrow and
spleen by 400 days of age. We also examined cellular expression of
the marker CD29 (b1 integrin; important for homing and
retention in lymphoid organs). We found an increased percentage
of CD29
+ cells in the marrow, with an even more pronounced
increase in the spleen of Drf1
2/2RhoB
2/2 mice relative to Drf1
2/2
RhoB
+/2 mice (Fig. 3C). These results are consistent with the
observed increase in myeloid cell proportion found by histopathol-
ogy (Fig. 1).
Finally, we analyzed the levels of TER-119 (erythroid-specific
marker) and CD71 (transferrin receptor; a marker of proliferating
erythroid precursors) in the marrow and spleen of Drf1
2/2RhoB
2/2
and Drf1
2/2RhoB
+/2 mice. While there were no differences in
the bone marrow, the levels of CD71
+ and TER-119
+ cells were
elevated in the spleens of 400-day-old Drf1
2/2RhoB
2/2 mice
(Fig. 4, A and B). An increase in erythroid precursors was also
evident in H&E-stained splenic sections (data not shown).
Consistent with this observation and the presence of splenic
EMH, we also found a substantial increase in splenic cells
undergoing S phase in 400-day-old Drf1
2/2RhoB
2/2 mice
relative to the number in Drf1
2/2RhoB
+/2 mice (Fig. 4C).
Discussion
MDS is thought to arise because of multiple alterations in a
hematopoietic stem cell [10]. We previously found that knocking
out mDia1 expression in mice leads to the age-dependent
development of myelodysplasia [6]. Here, we show that the
additional knockout of RhoB expression in Drf1-null mice
accelerates the progression to myelodysplasia. Several candidate
tumor suppressor genes in humans reside on the long arm of
chromosome 5 [8]. One of these genes is DIAPH1, which encodes
the actin assembly protein mDia1. While genetic ablation of
Figure 2. Peripheral blood from Drf1
2/2RhoB
2/2 mice show age-dependent abnormalities. A. Peripheral blood smears stained with Wright-
Giemsa from 400-day-old mice. Left and center panels are images at 40x; right panels are 60x. B. Total WBC count from peripheral blood. C. Platelet
numbers from peripheral blood CBC analysis. In both B and C, each point on scatter plot represents data from a single mouse (o=Drf1
2/2RhoB
+/2;
&=Drf1
2/2RhoB
2/2) (** denotes P#0.01).
doi:10.1371/journal.pone.0007102.g002
RhoB/mDia1 Knockout Mice
PLoS ONE | www.plosone.org 3 September 2009 | Volume 4 | Issue 9 | e7102mDia1 expression alone in mice resembles 5q- MDS, it is likely
that mDia1 acts in concert with multiple other genes on the same
commonly deleted region to suppress malignancy [8].
MDS can progress to a more advanced stage and ultimately
develop into leukemia. The transformation events involved in
disease progression are thought to include genes that contribute to
cell-cycle control, apoptosis, and differentiation [10]. The small
GTPase RhoB is required for apoptosis in response to DNA-
damaging agents and farnesyltransferase inhibitors [14,16].
Previous reports have shown that RhoB negatively regulates Akt
survival signaling and mediates apoptosis in a p53-dependent
manner [19,20]. Given its role in apoptosis and its known
interactions with the mDia formins, we hypothesized that deletion
of RhoB would enhance the progression of MDS in mice lacking
mDia1 expression. Our results support this hypothesis and further
substantiate our mouse model of age-associated myelodysplasia. It
is also interesting to speculate that loss of RhoB expression may
interfere with hematopoietic stem cell maintenance, since recent
work has highlighted a role for RhoB in stem cell self-renewal [21].
Together, these findings suggest that multiple mechanisms may
contribute to the myelodysplastic phenotype in our mice.
Our mouse model uniquely positions us to test some important
questions related to the in vivo role of RhoB in the anti-neoplastic
affects of FTIs. FTIs have been tested clinically to treat various
myelodysplasias, with varying degrees of efficacy [22]. But whether
FTIs can alleviate the disease phenotype in Drf1-null or
heterozygous mice and whether RhoB is required in vivo to
mediate this response remains to be determined.
Figure 3. Flow cytometry analysis of mouse bone marrow and splenic cells. A. Scatter plot showing the percentage of lymphocytes,
monocytes, and granulocytes from bone morrow. Open shapes represent Drf1
2/2RhoB
+/2 mice and filled shapes represent Drf1
2/2RhoB
2/2 mice (**
denotes P#0.01; *** denotes P#0.001). B. Scatter plot showing the percentage of lymphocytes, monocytes, and granulocytes from mice splenic
single-cell suspensions. Legend is the same as in A (** denotes P#0.01). C. Percentage of F4/80
+, CD11b
+, and CD29
+ cells from the bone marrow and
spleen of mice (* denotes P#0.05; ** denotes P#0.01) (o=Drf1
2/2RhoB
+/2; &=Drf1
2/2RhoB
2/2).
doi:10.1371/journal.pone.0007102.g003
RhoB/mDia1 Knockout Mice
PLoS ONE | www.plosone.org 4 September 2009 | Volume 4 | Issue 9 | e7102Our results point to the down-regulation of RhoB as a potential
marker for late-stage MDS, similar to its diminished expression in
other late-stage cancers [12,13]. Examination of the gene
expression profile of RhoB in human patient samples that have
a more advanced disease signature could help determine better
treatment options for patients diagnosed with MDS.
In summary, we show that mice lacking mDia1 and RhoB
expression progress to MDS faster than mice lacking mDia1 alone.
These data parallel observations of MDS in humans, in which
multiple alterations in hematopoietic stem cells contribute to
disease pathogenesis. Our mouse model will be useful in
characterizing the mechanism of disease progression further and
in testing potential therapeutics to treat this chronic disease.
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